An important characteristic of the E6 proteins derived from cancer-associated human papillomaviruses (HPVs) is their ability to target cellular proteins for ubiquitin-mediated degradation. Degradation of the p53 tumour suppressor protein by E6 is known to involve the cellular ubiquitin ligase, E6-AP; however, it is presently not known how E6 targets the Drosophila discs large (Dlg) tumour suppressor and the membrane-associated guanylate kinase inverted (MAGI) family of proteins for degradation. By using an in vitro E6-AP immunodepletion assay, these targets were tested for degradation in a E6-AP-dependent manner. The data showed clearly that E6 can direct the degradation of Dlg and the MAGI family of proteins in the absence of E6-AP in this in vitro system. These results provide compelling evidence for the role of E6-associated ubiquitin ligases other than E6-AP in the degradation of certain E6 targets.
The ubiquitin/26S proteasome pathway is a major route for the selective degradation of eukaryotic proteins. Through the removal of key regulatory components, the pathway helps to control many aspects of cell homeostasis, growth and development. High specificity within the ubiquitin system is achieved by the ubiquitin protein ligase family of E3 enzymes. These enzymes bind to the target substrates, either directly or indirectly, and catalyse the last step in the conjugation process [covalent attachment of ubiquitin to the substrate (Ciechanover, 1998; Ciechanover et al., 2000) ]. The first example of a viral protein that uses the proteasome machinery to direct the degradation of a cellular protein was provided by the human papillomavirus (HPV) E6 protein and its stimulation of the ubiquitination and degradation of the cellular tumour suppressor protein p53 (Scheffner et al., 1990; Werness et al., 1990) . In vitro studies in reticulocyte lysates have shown that the HPV E6 oncoprotein binds to a cellular protein of 100 kDa, termed E6-AP (Huibregtse et al., 1991 , which is the prototype of the HECT (homologous to E6-AP carboxyl terminus) domain-containing ubiquitin ligases . Under normal circumstances, p53 is regulated via the Mdm2 ubiquitin ligase and E6-AP has no role in this pathway (Haupt et al., 1997; Kubbutat et al., 1997) . However, in HPV-containing cells, the Mdm2 pathway is bypassed and p53 is degraded constitutively via the E6/E6-AP ubiquitin ligase complex (Scheffner et al., , 1994 Rolfe et al., 1995; Hengstermann et al., 2001) .
Although E6-induced loss of p53 is an important element of E6-induced cellular transformation, recent studies have identified a number of additional cellular targets of E6 that may also play an important role [reviewed by ; Thomas et al. (2002a) ]. The discovery that high-risk, but not low-risk, HPV E6 proteins can bind to the PDZ domain-containing proteins and target them for ubiquitin-mediated degradation was particularly interesting, considering that high-risk types cause lesions that can progress to cervical carcinoma, whereas the low-risk types are very rarely associated with malignancies (zur Hausen & Schneider, 1987) . PDZ domains are motifs of 80-90 aa, which are present in a variety of proteins that are involved in clustering of ion channels, signalling enzymes and adhesion molecules to specific structures at the membranecytoskeleton interface of polarized cells [reviewed by Kim (1997) ]. Among them is hScribble, a protein that is expressed at epithelial tight junctions, which has recently been shown to be a substrate for ubiquitination by the E6/E6-AP complex in vitro (Nakagawa & Huibregtse, 2000) . E6 oncoproteins were also shown to bind to the human homologue of the Drosophila discs large (Dlg) tumour suppressor (hDIg) and the membrane-associated guanylate kinase (MAGUK) inverted (MAGI) family of proteins and to induce their proteasome-mediated degradation (Gardiol et al., 1999; Glaunsinger et al., 2000; Thomas et al., 2001 Thomas et al., , 2002b . However, the mechanisms by which these proteins can be directed for degradation by E6 are still unclear (Pim et al., 2000 (Pim et al., , 2002 Thomas et al., 2001 Thomas et al., , 2002b .
Recently, we showed that a panel of inhibitory peptides exerted different effects on the ability of HPV E6 to direct the degradation of a number of its substrates. In addition, by using an E6-AP immunodepletion assay, we obtained evidence that MAGI-1 degradation was E6-AP-independent (Sterlinko Grm et al., 2004) . Therefore, the present study was initiated to investigate whether E6-directed degradation of the PDZ domain-containing proteins Dlg and MAGIs required the E6-AP ubiquitin ligase. We performed in vitro E6-AP immunodepletion assays to determine whether there were any differences in the E6-induced degradation of these targets in the presence or absence of E6-AP. To do this, HPV-16 and -18 E6, p53, hDlg and MAGI proteins were translated in vitro by using the TNT rabbit reticulocyte system (Promega) and incubated with rabbit polyclonal anti-E6-AP antibody (kindly provided by Martin Scheffner, Institute of Biochemistry, University of Cologne, Germany) for 30 min on ice, followed by adsorption of the immune complexes onto protein A-Sepharose beads. The supernatant fractions were then used as in vitro-translated proteins depleted of E6-AP. Immunodepletion with a pre-immune antibody was included as a negative control. To assess the effectiveness of the depletion, we first performed an anti-E6-AP Western blot on wheat-germ extract (Promega) and on untreated, pre-immune-depleted and E6-AP-depleted rabbit reticulocyte extract (Promega). As shown in Fig. 1 (a), no E6-AP was detected in wheat-germ extract, in contrast to rabbit reticulocyte extract, where a strong band was detected at 100 kDa, in agreement with previously published data (Huibregtse et al., 1991) . Immunodepletion with anti-E6-AP antibody effectively removed most of the E6-AP protein from the rabbit reticulocyte lysate (Fig. 1a) . In contrast, the control immunodepletion with pre-immune sera had little effect. These data showed that the polyclonal anti-E6-AP antibody raised against human E6-AP efficiently recognized the rabbit E6-AP in the rabbit reticulocyte lysate. This is in agreement with the very high degree of conservation in the E6-AP protein between species, with over 99 % homology between human and mouse E6-AP. Furthermore, one round of immunodepletion was sufficient to remove most of the E6-AP protein present within the lysate. As it has been demonstrated that E6-mediated degradation of p53 is E6-AP-dependent, we used this to test the effectiveness of our immunodepletion. In vitro-translated p53 was immunodepleted of E6-AP and incubated with similarly immunodepleted HPV-16 or -18 E6 for 30 min at 30 u C. The remaining p53 protein was then immunoprecipitated with rabbit polyclonal C4 antibody and the results obtained are shown in Fig. 1(b) . As can be seen, p53 was effectively degraded by E6 over the course of the assay in the sample that was immunodepleted with the pre-immune antibody (negative control). However, E6-mediated degradation of p53 was blocked in the E6-AP-depleted samples, in agreement with previous publications (Huibregtse et al., 1991 Scheffner et al., 1993) .
Having confirmed that by using the E6-AP immunodepletion procedure, we could block E6-mediated degradation of p53 efficiently, we then investigated the role of E6-AP in the E6-mediated degradation of Dlg and the MAGI family of proteins. Lysates containing radiolabelled E6, hDlg and the MAGI proteins were treated as described above and degradation assays were performed. We first investigated the effect of E6-AP immunodepletion on the E6-mediated degradation of Dlg. Assays were performed as for p53, except that the degradation assay required 2 h at 30 u C. After incubation, the amount of residual Dlg was assessed by immunoprecipitation with rabbit polyclonal anti-Dlg antibody ). The results obtained are shown in Fig. 2(a) . As can be seen, in samples that were immunodepleted of E6-AP, there was the same level of E6-mediated degradation of Dlg as that observed in samples that were immunodepleted with pre-immune antibody, demonstrating that E6-induced degradation of Dlg is indeed E6-AP-independent. We then proceeded to investigate the necessity for E6-AP in the E6-mediated degradation of three other PDZ domain-containing substrates: MAGI-1, -2 and -3 (Glaunsinger et al., 2000; Thomas et al., 2001 Thomas et al., , 2002b . MAGI-1, -2 and -3 and HPV-16 and -18 E6 were translated in vitro in rabbit reticulocyte lysate, immunodepleted as above and incubated at 30 u C for 60 min. The remaining proteins were immunoprecipitated by using rabbit polyclonal anti-WW antibody (specific for the conserved WW domain on MAGI-1) (Thomas et al., 2002b) and analysed by SDS-PAGE. The results obtained are shown in Fig. 2(b-d) . MAGI-1 was degraded to the same extent by HPV-18 E6 over the course of the assay in both the E6-APand pre-immune-depleted extracts (Fig. 2b) ; the same was true for HPV-16 E6-mediated degradation, as demonstrated previously (Sterlinko Grm et al., 2004) . The same was also true for MAGI-2 and -3, which were degraded efficiently in E6-AP-depleted extract by both HPV-16 and -18 E6 ( Fig. 2c  and d, respectively) . These results demonstrated that the ability of high-risk E6 proteins to direct the degradation of the PDZ domain-containing targets Dlg and MAGIs does not require the E6-AP ubiquitin ligase.
It has previously been shown that Dlg and MAGI proteins are targeted for ubiquitin-mediated degradation by the high-risk HPV E6 proteins in vivo (Gardiol et al., 1999; Glaunsinger et al., 2000; Thomas et al., 2002b) . To confirm that E6-mediated degradation of its target proteins in E6-AP-immunodepleted extracts was through the ubiquitinproteasome pathway, the degradation assay was repeated in the presence of either the proteasome inhibitor N-CbzLeu-Leu-Leu-H (Cbz) or DMSO as a control. As shown in Fig. 3 (upper panel) , the presence of HPV-16 E6 again resulted in a dramatic decrease in levels of MAGI-3 protein in mock-depleted and E6-AP-depleted extracts. In addition, the proteasome inhibitor Cbz significantly inhibited E6-mediated degradation of MAGI-3 in both extracts, confirming the involvement of the proteasome proteolytic pathway. Cbz treatment also efficiently blocked the degradation of MAGI-1, MAGI-2 and Dlg proteins by both oncoproteins (data not shown).
Previous studies have shown that there are many differences between the E6-mediated degradation of MAGUK proteins and the p53 protein. In contrast to the situation with p53 (Scheffner et al., 1990) , HPV-18 E6 binds more strongly to and induces degradation of hDlg and MAGI proteins more efficiently than HPV-16 E6 (Pim et al., 2000) . In addition, HPV-18 E6 can induce the degradation of Dlg in wheat-germ extract (Pim et al., 2000) , from which E6-AP is absent (Huibregtse et al., 1991 , and extensive mutational analysis of E6 has indicated that sequences within the amino-terminal half of the E6 protein, which are essential for p53 degradation, are largely dispensable for Degradation ( the degradation of Dlg (Pim et al., 2000) . This broadly covers the region of E6 that is required for high-affinity binding to E6-AP (Li & Coffino, 1996) . Lastly, low-risk HPV E6 proteins, which do not interact with E6-AP, can induce the degradation of Dlg when provided with a PDZ-binding consensus sequence (Pim et al., 2000) . All of these studies indicate that E6-AP is unlikely to be involved in the degradation of Dlg. In support of this, the data here show clearly that E6 can direct the degradation of Dlg and the MAGI proteins in the absence of the E6-AP ubiquitin ligase in an in vitro system. This strongly supports the existence of a second E6-associated ubiquitin ligase, identification of which is now a high priority. 
